Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Therapeutical antibodies > nivolumab


Sunday 13 July 2014


Nivolumab is an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.

Nivolumab, a drug in clinical trials also known as BMS-936558 or MDX1106, is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer. It has been approved for the treatment of advanced melanoma.